🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,013 results for “AB” Clear

  1. Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)

    phase 3 small molecule active

    1 trial

  2. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  3. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  4. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 3 small molecule active

    1 trial

  5. Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule

    Medice Arzneimittel Pütter GmbH & Co. KG

    Patients with ADHD (according to ICD-10 / DSM-5)

    phase 3 small molecule active

    1 trial

  6. Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet

    Pharma Mar S.A.

    Classic Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    1 trial

  7. Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet

    Pharma Mar S.A.

    Classic congenital adrenal hyperplasia

    phase 3 small molecule active

    1 trial

  8. Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  9. Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  10. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  11. Axatilimab (INCA034176)

    Incyte Biosciences Distribution B.V.

    Chronic Graft-Versus-Host Disease

    phase 3 small molecule active

    1 trial

  12. B013+Nab-Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Triple Negative Breast Cancer (TNBC)

    phase 3 small molecule completed

    1 trial

  13. BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  14. BARICITINIB, ADALIMUMAB, ADALIMUMAB, Baricitinib, BARICITINIB, BARICITINIB

    Eli Lilly Co.

    Uveitis

    phase 3 small molecule active

    1 trial

  15. BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  16. BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  17. BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension

    Eli Lilly Co.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  18. BAY 1841788, NUBEQA 300 mg film-coated tablets, Saruparib, ZYTIGA 250 mg tablets, Xtandi - 40 mg film-coated tablets, ZYTIGA 500 mg film-coated tablets, Placebo to match (PTM) tablets, Abiraterone Teva 500 mg film-coated tablets

    AstraZeneca AB

    Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  19. BAY 1841788, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  20. BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Chronic kidney disease

    phase 3 small molecule active

    1 trial

  21. BAY 94-8862, Placebo to Finerenone 10 film-coated tablets, Placebo to BAY 948862, BAY 948862, Placebo to Finerenone 20 film-coated tablets, Finerenone

    Bayer AG

    Proteinuria, Chronic kidney disease

    phase 3 small molecule active

    1 trial

  22. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  23. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  24. BENDAMUSTINE HYDROCHLORIDE, PREDNISOLONE , CYCLOPHOSPHAMIDE, LENALIDOMIDE, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, Golcadomide, Golcadomide, PEGFILGRASTIM, Golcadomide, BENDAMUSTINE HYDROCHLORIDE, RITUXIMAB, LENALIDOMIDE, RITUXIMAB, VINCRISTINE SULFATE, LENALIDOMIDE, LENALIDOMIDE, CYCLOPHOSPHAMIDE, Golcadomide, DOXORUBICIN HYDROCHLORIDE

    Celgene Europe Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources